Plant Name: Asarum heterotropoides f. schm. var. mandshuricum (maxim.) kitag.
Taxonomic Information:
Plant ID: NPO12468.2
Plant Latin Name: Asarum heterotropoides f. schm. var. mandshuricum (maxim.) kitag.
Taxonomy Genus: Asarum
Taxonomy Family: Aristolochiaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
93505-1
Used in Medicines:
Unknown.
Geographical Distribution:
Japan; Russia; South Africa
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| MAPK1; | |
| TP53; | |
| MAPT; LMNA; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.752E-07 | 7.351E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.687E-06 | 1.225E-02 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 2.362E-06 | 1.286E-02 | CYP1A2, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 7.417E-06 | 2.307E-02 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 7.417E-06 | 2.307E-02 | CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0019902; phosphatase binding | 2.051E-05 | 5.584E-02 | MAPK1, MAPT, TP53 |
| BP | GO:0051179; localization | GO:1903827; regulation of cellular protein localization | 3.154E-05 | 6.611E-02 | LMNA, MAPK1, MAPT, TP53 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 3.644E-05 | 6.611E-02 | CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.838E-05 | 6.611E-02 | CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 4.236E-05 | 7.096E-02 | MAPT, TP53 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 5.209E-05 | 7.757E-02 | CYP1A2, MAPK1 |
| BP | GO:0009987; cellular process | GO:0034605; cellular response to heat | 1.106E-04 | 1.338E-01 | MAPT, TP53 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.106E-04 | 1.338E-01 | CYP1A2, CYP3A4 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 2.461E-04 | 1.879E-01 | MAPK1, MAPT |
| CC | GO:0043226; organelle | GO:0016604; nuclear body | 1.575E-03 | 3.327E-01 | LMNA, MAPT, TP53 |
| CC | GO:0044464; cell part | GO:0030424; axon | 3.543E-03 | 4.608E-01 | MAPK1, MAPT |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.151E-05 | 1.301E-03 | LMNA, MAPK1, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 6.903E-05 | 1.813E-03 | MAPK1, MAPT, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 4.244E-05 | 1.599E-03 | MAPK1, TP53 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 4.244E-05 | 1.599E-03 | CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 1.603E-04 | 1.813E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 8.555E-05 | 1.813E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 1.381E-04 | 1.813E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 2.161E-04 | 1.813E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 1.966E-04 | 1.813E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 2.228E-04 | 1.813E-03 | MAPK1, TP53 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.720E-04 | 1.813E-03 | CYP1A2, CYP3A4 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.161E-04 | 1.813E-03 | CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.297E-04 | 1.813E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 2.580E-04 | 1.813E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 2.727E-04 | 1.813E-03 | MAPK1, TP53 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 2.436E-04 | 1.813E-03 | CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 4.053E-04 | 2.410E-03 | MAPK1, TP53 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.727E-04 | 1.813E-03 | CYP1A2, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 7.110E-04 | 3.776E-03 | MAPK1, TP53 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 7.351E-04 | 3.776E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.441E-04 | 2.160E-03 | CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.085E-03 | 5.109E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 9.018E-04 | 4.431E-03 | MAPK1, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 7.351E-04 | 3.776E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 2.082E-03 | 8.566E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05010 | Alzheimer's disease | 1.433E-03 | 6.476E-03 | MAPK1, MAPT |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 2.122E-03 | 8.566E-03 | MAPK1, TP53 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 1.749E-03 | 7.601E-03 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; TP53; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; |
| C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; TP53; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
